IECM
AMED

Intrinsic Edge Capital Management’s Amedisys AMED Stock Holding History

Intrinsic Edge Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-65,896
Closed -$17.4M – 217
2021
Q1 		$17.4M Buy
65,896
+50,896
+339% +$14.4M 1.19% 13
2020
Q4 		$4.4M Sell
15,000
-10,000
-40% -$2.56M 0.33% 102
2020
Q3 		$5.91M Buy
25,000
+14,000
+127% +$3.18M 0.4% 103
2020
Q2 		$2.18M Buy
+11,000
New +$2.05M 0.2% 162

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Intrinsic Edge Capital Management's AMED Position: Q2 2021 in Review

Intrinsic Edge Capital Management sold out of Amedisys (AMED) in Q2 2021, closing a stake of 65,896 shares — an estimated $17.4M sold.

Intrinsic Edge Capital Management first reported a position in AMED in Q2 2020 and held it in 4 quarters. The position peaked at $17.4M in Q1 2021. 375 funds tracked by Wall St. Rank hold AMED as of Q2 2021.

  • Intrinsic Edge Capital Management reported no remaining Amedisys position as of Q2 2021 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 65,896 Amedisys shares in Q2 2021, an estimated $17.4M.
  • Intrinsic Edge Capital Management first reported a position in Amedisys in Q2 2020 and held it in 4 quarters.
  • Intrinsic Edge Capital Management's Amedisys position peaked at $17.4M in Q1 2021.
  • 375 funds tracked by Wall St. Rank held Amedisys as of Q2 2021.

Based on Intrinsic Edge Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.